Agenus (AGEN) and Noetik announced a research collaboration to develop predictive biomarkers of response to Agenus’ clinical stage immuno-oncology combination, botensilimab and balstilimab. The collaboration harnesses Noetik’s proprietary virtual cell foundation models and large-scale, multimodal tumor data to uncover insights into the biology of tumor immunology. Together, the teams will deploy Noetik’s first-in-class foundation models directly on clinical results with the aim to enrich clinical efficacy. The collaboration aims to uncover clear, actionable biomarkers that can help predict which patients are most likely to respond to BOT/BAL treatment. Agenus will have exclusive rights to apply these insights in its drug development and commercialization efforts.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AGEN:
- International Paper, ImmunityBio, Agenus, Akebia, Apple: Trending by Analysts
- Agenus Announces Strategic Collaboration with Zydus
- Agenus price target raised to $6 from $4 at Baird
- Strategic Collaboration Between Agenus and Zydus Lifesciences Boosts Financial Position and Product Development
- Agenus upgraded to Buy from Neutral at H.C. Wainwright